

The Obesity Susceptibility Gene *Carboxypeptidase E* Links FoxO1 Signaling in Hypothalamic Pro-opiomelanocortin Neurons with Regulation of Food Intake

Leona Plum, Hua V. Lin, Roxanne Dutia, Jun Tanaka, Kumiko S. Aizawa, Michihiro Matsumoto, Andrea J. Kim, Niamh X. Cawley, Ji-Hye Paik, Y. Peng Loh, Ronald A. DePinho, Sharon L. Wardlaw and Domenico Accili

**SI Guide**

Supplementary Results

Seven Supplementary Figures

One Supplementary Table

## Supplementary Results

### $\alpha$ -MSH inhibits hypothalamic *Pcsk1*

We found reduced hypothalamic *Pcsk1* mRNA and protein levels in refed *Pomc-Foxo1*<sup>-/-</sup> mice (**Supplementary Fig. 6a–e**). Unlike *Cpe*, the decrease of *Pcsk1* was not confined to the ARC, but was also seen in the PVN, consistent with a paracrine effect of increased  $\alpha$ -Msh (**Supplementary Fig. 6b,c**). This decrease was unexpected, given that leptin sensitivity was increased (Fig. 2g), and that leptin increases *Pcsk1* in hypothalamic neurons. We therefore investigated whether the reduction of hypothalamic *Pcsk1* results from feedback inhibition by  $\alpha$ -Msh. We first analyzed the effect of  $\alpha$ -Msh on *Pcsk1* promoter activity in Neuro2A cells. Incubation with  $\alpha$ -Msh suppressed *Pcsk1* reporter gene activity by ~60% (**Supplementary Fig. 6f**). Likewise,  $\alpha$ -Msh reduced endogenous *Pcsk1* expression by ~50% in primary MBH cells (**Supplementary Fig. 6g**). To test if repression also occurs *in vivo*, we injected NDP- $\alpha$ -Msh ICV and analyzed *Pcsk1* expression. Consistent with the *in vitro* findings, NDP- $\alpha$ -Msh reduced *Pcsk1* in ARC and PVN (**Supplementary Fig. 6h,i**), but failed to affect *Cpe* (data not shown). These data demonstrate feedback inhibition of hypothalamic *Pcsk1* by  $\alpha$ -Msh and suggest that reduced *Pc1* in refed *Pomc-Foxo1*<sup>-/-</sup> mice is the result of increased  $\alpha$ -Msh.

### Supplementary Figure Legends

**Supplementary Figure 1** POMC neuron-specific FoxO1 ablation. **(a)** Representative hypothalamic GFP immunohistochemistry in *PomcCre-Gt(ROSA)26Sor<sup>tm2Sho</sup>* mice. 3V: third ventricle. **(b)** *Foxo1* and *Cre* genotyping. Arrows indicate loxP-flanked (*flox*, lower arrow) and recombined ( $\Delta$ , upper arrow) *Foxo1* alleles. Pi: pituitary; Hy: mediobasal hypothalamus; Bs: brainstem; Cx: cortex; Cb: cerebellum; Li: liver; Pa: pancreas; Wa: white adipocyte; Ba: brown adipocyte; Sm: skeletal muscle; Co: control. **(c)** Relative pituitary *Foxo1* expression in adult mice ( $n = 6$ ). **(d)** MBH *Pomc* and *Agrp* promoter ChIP. **(e)** Relative *Pomc* expression in pituitary of mice in (c). **(f)** Serum corticosterone levels in adult mice in the basal state and after 1-h restraint stress (females only) ( $n = 6$ ). Data are presented as means  $\pm$  SEM. \* =  $P < 0.05$ ; \*\*\* =  $P \leq 0.001$  by t-test.

**Supplementary Figure 2** Body length and body mass index. **(a)** Body mass index (BMI) of NCD-fed, 18-week-old female ( $n = 40-71$ ) and **(b)** male ( $n = 35-67$ ) mice. **(c, d)** Naso-anal body length of mice in (a, b). Data are presented as means  $\pm$  SEM. \*\* =  $P \leq 0.01$ ; \*\*\* =  $P \leq 0.001$  by unpaired t-test.

**Supplementary Figure 3** Energy expenditure and food intake. **(a)** Energy expenditure, plotted as 1-h running averages, **(b)** average energy expenditure during the light/day and dark/night phase, **(c)** total locomotion in the cage periphery, **(d)** respiratory quotient (RQ), and **(e)** percentage of NCD ingested during the light (light grey) and dark (dark grey) phase in adult male mice ( $n = 8$ ).

**Supplementary Figure 4** POMC neuron counts and neuropeptide mRNA levels. **(a)** POMC neuron numbers in 15-week-old male mice ( $n = 9$ ). **(b)** Ad libitum ( $n = 5$ ) and **(c)** refed ( $n = 14-17$ ) MBH mRNA expression in 18-week-old male mice. Data represent mean  $\pm$  SEM and are normalized by *Actb* levels. \* =  $P < 0.05$  by t-test.

**Supplementary Figure 5** MBH neuropeptide mRNA and peptide expression. **(a)** *Pomc* levels in 3- to 4-week-old mice ( $n = 4-6$ ) and **(b)** in 4- to 5-week-old ( $n = 3-4$ ) refed mice. **(c)** *Agrp* and *Pomc* in *ad libitum*-fed ( $n = 5$ ) and **(d)** refed ( $n = 14-17$ ) 18-week-old male mice. **(e, f)** *Agrp/Pomc* ratios in the animals shown in (c, d). Data represent mean  $\pm$  SEM. mRNA levels (but not ratios) are normalized by average neuron number in each genotype. \* =  $P < 0.05$  by unpaired t-test.

**Supplementary Figure 6**  $\alpha$ -MSH inhibits hypothalamic PC1. **(a)** Hypothalamic *Pcskl* in *ad libitum*-fed ( $n = 5$ ) and refed ( $n = 14-15$ ) male mice. Data are normalized by *Actb* and plotted as % of *ad libitum*-fed levels in WT. **(b)** *Pcskl* levels in ARC ( $n = 10-11$ ) and **(c)** PVN ( $n = 5-6$ ) of refed male mice. **(d)** Representative hypothalamic Pc1 and  $\beta$ -actin western blot and **(e)** quantitation of Pc1 protein levels in refed male mice ( $n = 13-14$ ). **(f)**  $\alpha$ -Msh regulates *Pcskl*-luciferase activity in Neuro2A cells co-transfected with plasmid *pEGFP-Mc4r* to express melanocortin-4 receptors. **(g)**  $\alpha$ -Msh regulates *Pcskl* in primary MBH cultures ( $n=6-21$ ). **(h)** *Pcskl* expression in ARC and **(i)** PVN of adult mice following ICV injection of NDP- $\alpha$ -Msh or saline control ( $n = 9-10$ ). Data are presented as means  $\pm$  SEM. # =  $P \leq 0.01$  in *ad libitum* vs. refed (same genotype) by ANOVA. \* =  $P$

<0.05; \*\* =  $P \leq 0.01$  WT vs. *Pomc-Foxo1*<sup>-/-</sup> untreated vs. treated (same condition) by ANOVA.

**Supplementary Figure 7** Pcsk2 expression and ghrelin levels. **(a)** MBH *Pcsk2* in refed male mice ( $n = 14-15$ ). Data are normalized by *Actb* levels. **(b)** Western blot of the 64–66kDa Pc2 isoform in MBH extracts of refed male mice. Actin was used as loading control. **(c)** Serum ghrelin levels in adult male mice. Samples were obtained one hour before lights off ( $n = 7$ ). Data are presented as means  $\pm$  SEM.


## Supplementary References

1. Fox, D.L. & Good, D.J. Nescient helix-loop-helix 2 interacts with signal transducer and activator of transcription 3 to regulate transcription of prohormone convertase 1/3. *Mol Endocrinol* **22**, 1438-1448 (2008).
2. Nakashima, K., Narazaki, M. & Taga, T. Overlapping and distinct signals through leptin receptor (OB-R) and a closely related cytokine signal transducer, gp130. *FEBS Lett* **401**, 49-52 (1997).
3. Sanchez, V.C., et al. Regulation of hypothalamic prohormone convertases 1 and 2 and effects on processing of prothyrotropin-releasing hormone. *J Clin Invest* **114**, 357-369 (2004).
4. Kitamura, T., et al. Forkhead protein FoxO1 mediates Agrp-dependent effects of leptin on food intake. *Nat Med* **12**, 534-540 (2006).
5. Kim, E.M., Grace, M.K., O'Hare, E., Billington, C.J. & Levine, A.S. Injection of alpha-MSH, but not beta-endorphin, into the PVN decreases POMC gene expression in the ARC. *Neuroreport* **13**, 497-500 (2002).
6. Lee, M., et al. Effects of selective modulation of the central melanocortin-3-receptor on food intake and hypothalamic POMC expression. *Peptides* **29**, 440-447 (2008).

**Supplementary Table 1** Neuropeptide levels in MBH of re-fed mice





Peptide	WT	<i>Pomc-Foxo1</i> <sup>-/-</sup>
ACTH	166 ± 19	149 ± 14
POMC	220 ± 20	195 ± 16
β-EP	555 ± 28	543 ± 32
αMSH	306 ± 20	309 ± 20
AgRP	343 ± 25	299 ± 18
POMC/αMSH	0.75 ± 0.06	0.66 ± 0.06

Data are presented as mean fmol/mg protein ± SEM ( $n = 13-18$ ),  $P = \text{NS}$ .








Plum, Supplementary Figure 1










Plum, Supplementary Figure 2




Plum, Supplementary Figure 3








**a**



**b**



**c**

